On April 14, 2026 ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, reported that it has selected Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, as a strategic technology partner. ImmuVia will deploy Quantori’s Q-Scientist platform to streamline computational workflows across its preclinical programs, with the goal of compressing development timelines and reducing costs as it advances its lead candidate, IMV-M, towards clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Science: A New Approach to an Old Problem
Death Receptor agonists – molecules designed to trigger a tumor cell’s built-in self-destruct program (apoptosis) – have long been considered one of the most promising approaches in oncology. Yet clinical programs have failed, stymied by insufficient potency, off-target toxicity, or both.
ImmuVia’s proprietary Cancerlysin platform was built to solve this problem at the molecular level. Its lead candidate is IMV-M, a bispecific antibody that functions as a conditional switch: it first binds MUC16 – a protein overexpressed on ovarian, pancreatic, and other solid tumors – and only then activates the Death Receptor 5 pathway via clustering to trigger apoptosis. The result is a molecule specifically engineered for high-potency tumor killing with a wide therapeutic window.
The Partnership: Doing the Work Faster and at Lower Cost
The complexity of Cancerlysin programs generates significant computational demands across molecular modeling, pharmacokinetic simulation, and regulatory data preparation. Rather than build these capabilities in-house, ImmuVia has chosen to partner with Quantori, whose Q-Scientist platform provides an integrated environment for orchestrating these workflows. Under the partnership, Quantori will support ImmuVia’s preclinical programs in three key areas:
Molecular Modeling and Simulation: Running computational analyses of Cancerlysin molecules’ binding behavior and selectivity profile, reducing the number of iterative bench experiments required to optimize candidates.
In Silico Pharmacology: Modeling Cancerlysin molecule’s pharmacokinetic and pharmacodynamic properties across tumor microenvironments, enabling the team to test hypotheses computationally before committing to further costly in vivo studies.
Regulatory Data Preparation: Transforming high-volume laboratory and analytical data into structured, submission-ready documentation, compressing timelines for IND-enabling toxicology and CMC deliverables.
Executive Commentary
"ImmuVia is a biology company. Our edge is the science behind IMV-M and the Cancerlysin platform," said Iosif M. Gershteyn, Chief Executive Officer at ImmuVia. "What we need from technology partners is straightforward: help us do our work faster and at lower cost. Quantori’s platform does exactly that. It lets a lean team operate with the analytical throughput of a large organization, that’s a practical advantage we intend to leverage."
"What makes this collaboration compelling is the quality of the underlying science," said Yuriy Gankin, PhD, Chief Scientific Officer at Quantori. "ImmuVia’s platform represents a genuinely differentiated approach to harnessing the biology of apoptosis, and the computational demands of a program this sophisticated are exactly where Q-Scientist delivers the most value. We can construct detailed in silico models of IMV-M’s behavior – its conformational dynamics, its interactions within the tumor microenvironment – and deliver those insights at a speed and cost that would be impossible to replicate through traditional methods."
(Press release, ImmuVia, APR 14, 2026, View Source [SID1234664373])